Literature DB >> 12060443

Cervical cancer should be considered as a rare complication of oncogenic HPV infection rather than a STD.

Theo J M Helmerhorst1, C J L M Meijer.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12060443     DOI： 10.1046/j.1525-1438.2002.t01-3-01126.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN： 1048-891X            Impact factor:   3.437


× No keyword cloud information.
  8 in total

1.  Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate.

Authors:  N W J Bulkmans; S Bulk; M S Ottevanger; L Rozendaal; S M Hellenberg; F J van Kemenade; P J F Snijders; A J P Boeke; C J L M Meijer
Journal:  J Clin Pathol       Date:  2006-08-30       Impact factor: 3.411

2.  Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.

Authors:  Wen-Fang Cheng; Chien-Nan Lee; Yi-Ning Su; Ming-Cheng Chang; Wen-Chun Hsiao; Chi-An Chen; Chang-Yao Hsieh
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

3.  A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions.

Authors:  A G Bais; I Beckmann; J Lindemans; P C Ewing; C J L M Meijer; P J F Snijders; T J M Helmerhorst
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

Review 4.  Human Immunodeficiency Virus and Human Papilloma Virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful.

Authors:  Sjoerd H van der Burg; Joel M Palefsky
Journal:  J Transl Med       Date:  2009-12-18       Impact factor: 5.531

5.  Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients.

Authors:  Alfonso Ferrara; Marion Nonn; Peter Sehr; Carola Schreckenberger; Michael Pawlita; Matthias Dürst; Achim Schneider; Andreas M Kaufmann
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-30       Impact factor: 4.553

6.  IL-17A promotes the migration and invasiveness of cervical cancer cells by coordinately activating MMPs expression via the p38/NF-κB signal pathway.

Authors:  Minjuan Feng; Yidong Wang; Kunlun Chen; Zhuoqiong Bian; Qing Gao
Journal:  PLoS One       Date:  2014-09-24       Impact factor: 3.240

7.  Cytokine release in HR-HPV(+) women without and with cervical dysplasia (CIN II and III) or carcinoma, compared with HR-HPV(-) controls.

Authors:  Aagje G Bais; Ilse Beckmann; Patricia C Ewing; Marinus J C Eijkemans; Chris J L M Meijer; Peter J F Snijders; Theo J M Helmerhorst
Journal:  Mediators Inflamm       Date:  2007       Impact factor: 4.711

8.  Immunologic Control of Mus musculus Papillomavirus Type 1.

Authors:  Joshua W Wang; Rosie Jiang; Shiwen Peng; Yung-Nien Chang; Chien-Fu Hung; Richard B S Roden
Journal:  PLoS Pathog       Date:  2015-10-23       Impact factor: 6.823
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.